Biocept is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. Co.'s assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, show progression or be used for monitoring in order to identify specific resistance mechanisms. Co. has commercialized its Target-Selector assays for a number of solid tumor indications such as: breast cancer, non-small cell lung cancer, gastric cancer, prostate cancer, and ovarian cancer. The BIOC stock yearly return is shown above.
The yearly return on the BIOC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BIOC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|